04_03 Metastatic Castrate Sensitive Prostate Cancer

1. The chemotherapy revolution in prostate cancer
2. Role of ARATs in earlier disease states
3. Triple therapy (chemotherapy, ADT, and ARAT)
4. Considerations for frailer patients with indolent disease

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Hussain M et al.. J Clin Oncol. 2023;41(20):3595-3607. doi:10.1200/JCO.23.00041

2.           Smith MR et al. NEJM. 2022;386(12):1132-1142. doi:10.1056/NEJMOA2119115/

3.           Fizazi K et al. Lancet. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1

4.           Sweeney CJ et al. Lancet Oncol. 2023;24(4):323-334. doi:10.1016/S1470-2045(23)00063-3

5.           Wenzel M, et al. Prostate Cancer and Prostatic Diseases 2021 25:2. 2021;25(2):139-148. doi:10.1038/s41391-021-00395-4

6.           Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0

7.           James ND et al. NEJM. 2017;377(4):338-351. doi:10.1056/NEJMOA1702900/SUPPL_FILE/

8.           Fizazi K, et al. Lancet Oncol. 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8

9.           James ND et al. Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

10.        Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0

11.        Sweeney CJ et al. NEJM. 2015;373(8):737-746. doi:10.1056/NEJMOA1503747/SUPPL_FILE\

12.        James ND et al. The Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

13.        Fizazi K et al. NEJM. 2017;377(4):352-360. doi:10.1056/NEJMOA1704174

14.        Tannock et al. NEJM 2004;351(15):1502-1512. doi:10.1056/NEJMOA040720

15.        Petrylak DP et al.. NEJM. 2004;351(15):1513-1520. doi:10.1056/NEJMOA041318

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology